A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Terminated · Phase 1 · NCT04272203
Conditions: Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
At a glance
- Research payments reported, 2025
- $4,724
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 14
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-184 (drug)
- Dates
- Started 2020-05-05; completion 2022-06-27
- Results posted
- Not yet
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC). AML (blood cancer) is cancer of the white blood cells (WBC). NSCLC (solid tumor) is a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine recommended phase 2 dose (RP2D) and to see if the study drug is safe and able to treat patients who have AML and NSCLC. ABBV-184 is an investigational drug being developed for treatment of cancer. The study has two arms and two phases: AML arm and NSCLC arm; dose escalation and dose expansion pha…
From ClinicalTrials.gov, last updated 2022-09-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $4,724 in research payments for this study in 2025 (35 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $4,724
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.